Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer

Background: Metastatic papillary thyroid carcinoma typically appears in local lymph nodes. Skin metastases are rare. Purpose: A man with progressive metastatic papillary thyroid carcinoma who developed a cutaneous metastasis on his nose is described. The clinical manifestations of metastatic pap...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Philip R. Cohen
Formato: article
Lenguaje:EN
Publicado: Mattioli1885 2015
Materias:
Acceso en línea:https://doaj.org/article/de34babf467340c3af8b0ef4fff20a39
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:de34babf467340c3af8b0ef4fff20a39
record_format dspace
spelling oai:doaj.org-article:de34babf467340c3af8b0ef4fff20a392021-11-17T08:31:28ZMetastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer10.5826/dpc.0504a032160-9381https://doaj.org/article/de34babf467340c3af8b0ef4fff20a392015-10-01T00:00:00Zhttp://dpcj.org/index.php/dpc/article/view/32https://doaj.org/toc/2160-9381 Background: Metastatic papillary thyroid carcinoma typically appears in local lymph nodes. Skin metastases are rare. Purpose: A man with progressive metastatic papillary thyroid carcinoma who developed a cutaneous metastasis on his nose is described. The clinical manifestations of metastatic papillary thyroid carcinoma to skin are reviewed. Methods: PubMed was used to search the following terms, separately and in combination: basal, cancer, carcinoma, cell, cutaneous, kinase, inhibitor, metastases, nose, papillary, rearranged during transfection, receptor, RET, thyroid, tyrosine, vandetanib. Results: Pathologic changes observed on the biopsy of the man’s nose lesion were similar to those of his original cancer. Genomic evaluation of the tumor revealed an aberration involving the rearranged during transfection (RET) receptor tyrosine kinase. The residual tumor was excised. Treatment with vandetanib, a RET inhibitor was initiated; his metastatic disease has been stable, without symptoms or recurrent cutaneous metastasis, for 2 years following the discovery of his metastatic nose tumor. Conclusions: Papillary thyroid carcinoma with skin metastases is rare. Nodules usually appear on the scalp or neck; the thyroidectomy scar is also a common site. Metastatic tumor, albeit infrequently, can present as a nose lesion. The prognosis for patients with cutaneous metastases from papillary thyroid carcinoma is poor. However, with the ability to test the tumor for genomic aberrations, molecular targeted therapies—such as tyrosine kinase inhibitors—may provide extended survival in these individuals. Philip R. CohenMattioli1885articlebasalcancercarcinomacellcutaneouskinaseDermatologyRL1-803ENDermatology Practical & Conceptual (2015)
institution DOAJ
collection DOAJ
language EN
topic basal
cancer
carcinoma
cell
cutaneous
kinase
Dermatology
RL1-803
spellingShingle basal
cancer
carcinoma
cell
cutaneous
kinase
Dermatology
RL1-803
Philip R. Cohen
Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
description Background: Metastatic papillary thyroid carcinoma typically appears in local lymph nodes. Skin metastases are rare. Purpose: A man with progressive metastatic papillary thyroid carcinoma who developed a cutaneous metastasis on his nose is described. The clinical manifestations of metastatic papillary thyroid carcinoma to skin are reviewed. Methods: PubMed was used to search the following terms, separately and in combination: basal, cancer, carcinoma, cell, cutaneous, kinase, inhibitor, metastases, nose, papillary, rearranged during transfection, receptor, RET, thyroid, tyrosine, vandetanib. Results: Pathologic changes observed on the biopsy of the man’s nose lesion were similar to those of his original cancer. Genomic evaluation of the tumor revealed an aberration involving the rearranged during transfection (RET) receptor tyrosine kinase. The residual tumor was excised. Treatment with vandetanib, a RET inhibitor was initiated; his metastatic disease has been stable, without symptoms or recurrent cutaneous metastasis, for 2 years following the discovery of his metastatic nose tumor. Conclusions: Papillary thyroid carcinoma with skin metastases is rare. Nodules usually appear on the scalp or neck; the thyroidectomy scar is also a common site. Metastatic tumor, albeit infrequently, can present as a nose lesion. The prognosis for patients with cutaneous metastases from papillary thyroid carcinoma is poor. However, with the ability to test the tumor for genomic aberrations, molecular targeted therapies—such as tyrosine kinase inhibitors—may provide extended survival in these individuals.
format article
author Philip R. Cohen
author_facet Philip R. Cohen
author_sort Philip R. Cohen
title Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
title_short Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
title_full Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
title_fullStr Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
title_full_unstemmed Metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
title_sort metastatic papillary thyroid carcinoma to the nose: report and review of cutaneous metastases of papillary thyroid cancer
publisher Mattioli1885
publishDate 2015
url https://doaj.org/article/de34babf467340c3af8b0ef4fff20a39
work_keys_str_mv AT philiprcohen metastaticpapillarythyroidcarcinomatothenosereportandreviewofcutaneousmetastasesofpapillarythyroidcancer
_version_ 1718425769941663744